Molecular Diagnostics
References 1 FDA Critical Path Opportunities Report March 2006. 2 European Union Seventh Framework Programme (2007-2013). 3 Reichert, JM and Wenger, JB (2008). Development trends for new cancer therapeutics and vaccines. Drug Discovery Today 13:30. 4
http://blogs.forbes.com/ robertlangreth/2010/08/06/why -pfizer-cant-cure-cancer/.
will exclude patients from new drugs. He argues that the paradigm of targeted therapy is inherently flawed and it may be time to go back to the begin- ning: more resource should be invested into early detection by imaging and improved surgical tech- niques. Perhaps it is time to shift emphasis from treatment to true diagnostics. The technology is available, with NGS and mass-spec leading the way, however diagnostics development needs further incentivising at the academic and research level. Pharmas are not about to drop research on target- ed drugs in favour of diagnostic tests, I suspect the economics do not work, and drugs will always be needed in any case. Perhaps a change in perspective is called for.
DDW
Dr Cliff Murray is currently Head of R&D at Source Bioscience plc having joined the company in January 2005. Prior to that, he was Reader in Oncology at Nottingham University and Director of the CRUK Tumour Cytokine Biology Group since 1994. The interests of his group included tumour angiogenesis and novel mechanisms employed by tumours to evade the host immune response. Cliff has a BSc in Biochemistry from St Andrews and a PhD in Pathology and Biochemistry from Cambridge.
62 Drug Discovery World Spring 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80